Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex in penetrating keratoplasty
NCT02834260Phase 2Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ozurdex in corneal graft rejection (CGR), sponsored by CHU Saint-Etienne. Started Jan 2017; status: completed.
02
Drugs
ozurdex
03
Conditions
corneal graft rejection (CGR)
Beyond the preview
Go deeper on NCT02834260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834260.